UPPER EXTREMITY PRP AND STEM CELL RESEARCH
Here we list important shoulder, elbow, and hand/wrist basic science and clinical research on the use of PRP and stem cells in musculoskeletal conditions. This list is constantly reviewed and updated as a reference source and to help guide our treatment recommendations.
As a research institute, The Dallas PRP and Stem Cell Institute collects registry data on all of our PRP and Stem Cell treatments to help fine tune our patient care and to publish in peer reviewed journals so that we may contribute to this rapidly growing area of orthopedics.
Randelli P, Randelli F, Ragone V, Menon A, D'Ambrosi R, Cucchi D, Cabitza P, Banfi G.
Biomed Res Int. 2014;2014:129515.
Stem cells therapies represent a novel frontier in the management of rotator cuff disease that required further basic and clinical research.
Effectiveness of Platelet-rich Plasma Injection for Rotator Cuff Tendinopathy: A Prospective Open-label Study.
Scarpone M, Rabago D, Snell E, Demeo P, Ruppert K, Pritchard P, Arbogast G, Wilson JJ, Balzano JF.
Glob Adv Health Med. 2013 Mar;2(2):26-31.
A single ultrasound-guided, intralesional injection of PRP resulted in safe, significant, sustained improvement of pain, function, and MRI outcomes in participants with refractory RCT.
Paper presented at 2014 RSNA meeting in Chicago
A retrospective study with 240 patients in 2 groups...one with PRP injection and one with medicine/therapy. MRI done before injecting PRP into tendon defect and at 4 years after injection. For group getting PRP injection: 28% improvement by MRI and 58% improvement by VAS at 4 years.
Paper not published as of 2/2015 according to pubmed.com
Efficacy of platelet-rich plasma for chronic tennis elbow: a double-blind, prospective, multicenter, randomized controlled trial of 230 patients.
Mishra AK, Skrepnik NV, Edwards SG, Jones GL, Sampson S, Vermillion DA, Ramsey ML, Karli DC, Rettig AC.
Am J Sports Med. 2014 Feb;42(2):463-71.
No significant differences were found at 12 weeks in this study. At 24 weeks, however, clinically meaningful improvements were found in patients treated with leukocyte-enriched PRP compared with an active control group.
Comparative effectiveness of injection therapies in lateral epicondylitis: a systematic review and network meta-analysis of randomized controlled trials.
Krogh TP, Bartels EM, Ellingsen T, Stengaard-Pedersen K, Buchbinder R, Fredberg U, Bliddal H, Christensen R.
Am J Sports Med. 2013 Jun;41(6):1435-46.
This systematic review and network meta-analysis of randomized controlled trials found a paucity of evidence from unbiased trials on which to base treatment recommendations regarding injection therapies for lateral epicondylitis.
Podesta L, Crow SA, Volkmer D, Bert T, Yocum LA. Am J Sports Med. 2013 Jul;41(7):1689-1694.
This was a retrospective review of 34 athletes with MRI documented partial thickness UCL tears. All had failed at least 2 months of nonoperative treatment and an attempt to return to play. All patients had one injection of PRP at the UCL. Average follow-up was 70 weeks. There were significant decreases in medial elbow joint space opening under valgus stress and in KJOC and DASH outcome scores. 88% returned to same level of play without complaints. 1/34 had persistent UCL instability and had surgery.
Platelet Rich Plasma Can Be Used To Successfully Treat Elbow Ulnar Collateral Ligament Insufficiency In High Level Throwers
Dines JS, Williams PN, ElAttrache N, Conte S, Tomcyzk T, Osbahr DC, Dines DM, Bradley J, Ahmad CS. Am J Orthop. 2016 Jul-Aug;(45), 296-300.
Retrospective review of 44 baseball players (6 pro, 14 college, 24 high school) treated with PRP for partial thickness UCL tears. 16 had 1 injection, 6 had 2 injections, and 22 had three injections. Average age was 17 years. Mean time to return to throw was 5 weeks. Mean time to return to competition was 3 months. These outcomes are significantly better than previously reported conservative treatment outcomes.